Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 100/100

Failure Rate

66.7%

4 terminated/withdrawn out of 6 trials

Success Rate

0.0%

-86.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 0 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 1

6(100.0%)

6Total

Phase 1(6)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT05780034Phase 1Recruiting

A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies

Role: lead

NCT05654532Phase 1Active Not Recruiting

Study of AC699 in Patients With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Locally Advanced or Metastatic Breast Cancer

Role: lead

NCT05241613Phase 1Terminated

A Study of AC176 for the Treatment of Metastatic Castration Resistant Prostate Cancer

Role: lead

NCT05080842Phase 1Terminated

A Study of AC682 for the Treatment of Locally Advanced or Metastatic ER+ Breast Cancer

Role: lead

NCT05489679Phase 1Terminated

A Study of AC682 In Chinese Patients With ER+/HER2- Locally Advanced or Metastatic Breast Cancer

Role: lead

NCT05673109Phase 1Terminated

A Study of AC176 for the Treatment of Metastatic Castration Resistant Prostate Cancer

Role: lead

All 6 trials loaded